• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Phase Forward reports 26% increase in third quarter revenue

Phase Forward reports 26% increase in third quarter revenue

October 30, 2006
CenterWatch Staff

Waltham, Mass.-based Phase Forward reported a 26% increase in third quarter 2006 revenues compared with the same period in 2005. The company reported third quarter revenues of $28 million, up from $22.2 million last year. For the fourth quarter of 2006, the company reported it expects revenues to be between $29.2 and $30.0 million. Income from operations was $4 million, showing a margin of 14.2% and an increase of 66% from the prior year period. The company reported expected revenues for the entire 2006 fiscal year to be between $105.6 and $106.4 million. On non-GAAP basis, the company expects EPS between $0.37 and $0.38.

The company also announced it signed contracts with Massachusetts General Hospital, Mitsubishi Pharma and Genzyme during the quarter. All three projects will use Phase Forward’s web-based EDC solution InForm. The company also announced that the Aurum Institute for Health Research has implemented the Inform EDC solution in a landmark 60,000 subject tuberculosis trial at 20 South African gold mines. The study, called Thibela TB, will be paperless and largely wireless, due to the remoteness of some of the sites. It will run for more than two years. In South Africa’s gold mines it is reported that the incidence of TB has more then doubled in the last few years and is typically fatal in patients with AIDS, the countries largest health crisis.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing